Alba Fiorentino: An oligometastatic lung cancer case report with a durable complete metabolic response
Alba Fiorentino, Associate Professor of Radiation Oncology at LUM University of Medicine, shared a post on LinkedIn, about a recent paper by her as a co-author, published in Current Oncology.
“We reported an oligometastatic lung cancer case report with a durable complete metabolic response (3 years) treated by stereotactic radiotherapy (SRT) for brain metastases, and hypofractionated RT (hypo-RT) for primary tumor and immune checkpoint inhibition (ICI).
The emergence of targeted therapy and immunotherapy has transformed the treatment of NSCLC, resulting in significant enhancements in survival rates; patients with stage IV oncogene-negative, PDL1-negative NSCLC continue to experience a grim prognosis.
The role of ablation treatment, including surgery and radiotherapy (RT), has been assessed in the current scenario. Numerous studies indicate that the 5-year overall survival (OS) rate for patients with limited metastases who underwent surgery or ablation at all disease sites ranges from 29% to 45%.
Consequently, treatment strategies for these patients should be performed, and the use of complete metabolic response in patients with brain and bone metastases from NSCLC potentially curative treatment, rather than merely palliative, should be increased.
In the present case, several scenarios were examined:
- The Role of RT in Oligometastatic NSCLC
- The Role of Hypo-RT or Ablative RT in Anti-Tumor Immunity
- The Volume Reduction in RT Increases the Immunity Response
- The Timing of ICI/RT
- The Role of ICI Acute Toxicity.”
Authors: Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Giammarco Surico, Alba Fiorentino et al.
More posts featuring Alba Fiorentino.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023